REGENXBIO to Host Conference Call on March 5 to Discuss Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights

Rhea-AI Summary

REGENXBIO (Nasdaq: RGNX) will host a conference call on Thursday, March 5, 2026 at 8:00 a.m. ET to discuss fourth-quarter and full-year results for the period ended December 31, 2025, and operational highlights.

Investors can register for the webcast, analysts can request Q&A access, and a replay will be posted about two hours after the call.

Key Figures

Conference date: March 5, 2026 Start time: 8:00 a.m. ET Fiscal year end: December 31, 2025 +2 more

5 metrics

Conference date March 5, 2026 Scheduled call to discuss Q4 and full-year 2025 results

Start time 8:00 a.m. ET Earnings and operational highlights conference call

Fiscal year end December 31, 2025 Period covered by Q4 and full-year results

Replay availability Approximately two hours Delay before webcast replay is posted to investor website

Early join time 15 minutes Recommended time for participants to join before call start

Market Reality Check

Price: $8.08 Vol: Volume 561,621 is 0.48x t...

low vol

$8.08 Last Close

Volume Volume 561,621 is 0.48x the 20-day average, indicating subdued trading ahead of the call. low

Technical Shares at $8.08 are trading below the $10.56 200-day moving average and about 50% under the 52-week high of $16.19.

Peers on Argus

RGNX was up 1.76% pre-announcement with mixed biotech peers: ARCT +6.49%, BCYC +...

RGNX was up 1.76% pre-announcement with mixed biotech peers: ARCT +6.49%, BCYC +2.74%, KOD +4.44%, while REPL -1.53% and ATYR -0.95%. No coordinated sector move is indicated.

Previous Conferences,earnings Reports

5 past events · Latest: Oct 29 (Neutral)

Same Type Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Oct 29	Earnings call notice	Neutral	-2.4%	Scheduled Q3 2025 earnings and operational highlights conference call.
Jul 31	Earnings call notice	Neutral	-2.7%	Announced Q2 2025 results call with webcast and analyst Q&A details.
Apr 30	Earnings call notice	Neutral	+2.3%	Set date for Q1 2025 financial results and operational update call.
Feb 26	Earnings call notice	Neutral	-1.1%	Scheduled call for Q4 and full-year 2024 results and updates.
Oct 30	Earnings call notice	Neutral	-2.4%	Announced Q3 2024 financial results and highlights conference call.

Pattern Detected

Prior earnings-call scheduling headlines with the same tag have been followed by modest share moves, with an average 24h reaction of about -1.27% across five events.

Recent Company History

Over the past year, RGNX has regularly issued "conferences,earnings" notices to schedule quarterly and full-year results calls. Five such announcements from Oct 30, 2024 through Oct 29, 2025 framed upcoming earnings discussions and operational updates. Price reactions around these scheduling releases were generally modest, with an average move of -1.27%. Today’s notice for the March 5, 2026 call continues this established communication pattern ahead of reporting Q4 and full-year 2025 results.

Historical Comparison

-1.3% avg move · Over the last five "conferences,earnings" scheduling releases, RGNX averaged a -1.27% next-day move,...

conferences,earnings

-1.3%

Average Historical Move conferences,earnings

Over the last five "conferences,earnings" scheduling releases, RGNX averaged a -1.27% next-day move, suggesting typically modest reactions to similar announcements.

The company has consistently used conference-call notices to book quarterly and full-year earnings discussions, maintaining a steady cadence of results communication from 2024 through 2025.

Regulatory & Risk Context

Active S-3 Shelf · $300,000,000

Shelf Active

Active S-3 Shelf Registration 2025-11-26

$300,000,000 registered capacity

An effective S-3 shelf filed on Nov 26, 2025 allows RGNX to offer up to $300,000,000 of various securities over time, with proceeds earmarked for general corporate purposes including trials, working capital and potential acquisitions.

Market Pulse Summary

This announcement sets the date and logistics for REGENXBIO’s March 5 call to review Q4 and full-yea...

Analysis

This announcement sets the date and logistics for REGENXBIO’s March 5 call to review Q4 and full-year 2025 results and operational highlights. It follows a consistent pattern of quarterly and annual conference-call notices seen throughout 2024–2025. Given recent regulatory and financing disclosures, the substantive update will come from the details shared on that call, including any commentary on cash runway, development plans and responses to prior FDA actions.

AI-generated analysis. Not financial advice.

ROCKVILLE, Md., Feb. 25, 2026 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that it will host a conference call on Thursday, March 5, at 8:00 a.m. ET to discuss its financial results for the fourth quarter and full year ended December 31, 2025, and operational highlights.

Listeners can register for the webcast via this link. Analysts wishing to participate in the question and answer session should use this link. A replay of the webcast will be available via the company's investor website approximately two hours after the call's conclusion. Those who plan on participating are advised to join 15 minutes prior to the start time.

ABOUT REGENXBIO Inc.
REGENXBIO is a biotechnology company on a mission to improve lives through the curative potential of gene therapy. Since its founding in 2009, REGENXBIO has pioneered the field of AAV gene therapy. REGENXBIO is advancing a late-stage pipeline of one-time treatments for rare and retinal diseases, including RGX-202 for the treatment of Duchenne; clemidsogene lanparvovec (RGX-121) for the treatment of MPS II and RGX-111 for the treatment of MPS I, both in partnership with Nippon Shinyaku; and surabgene lomparvovec (ABBV-RGX-314) for the treatment of wet AMD and diabetic retinopathy, in collaboration with AbbVie. Thousands of patients have been treated with REGENXBIO's AAV platform, including those receiving Novartis' ZOLGENSMA®. REGENXBIO's investigational gene therapies have the potential to change the way healthcare is delivered for millions of people. For more information, please visit WWW.REGENXBIO.COM.

Contacts:
Dana Cormack
Corporate Communications
dcormack@regenxbio.com 

Investors:
George E. MacDougall
Investor Relations
IR@regenxbio.com 

View original content to download multimedia:https://www.prnewswire.com/news-releases/regenxbio-to-host-conference-call-on-march-5-to-discuss-fourth-quarter-and-full-year-2025-financial-results-and-operational-highlights-302696540.html

SOURCE REGENXBIO Inc.

FAQ

When is REGENXBIO's (RGNX) conference call to discuss 2025 financial results?

The conference call is scheduled for Thursday, March 5, 2026 at 8:00 a.m. ET. According to the company, the call will cover fourth-quarter and full-year results for the period ended December 31, 2025, plus operational highlights and a Q&A session.

How can investors access REGENXBIO's (RGNX) March 5, 2026 webcast?

Investors can register for the live webcast via the company's investor website registration link. According to the company, a replay will be available on the investor website approximately two hours after the call concludes.

What should analysts do to participate in REGENXBIO's (RGNX) March 5 Q&A session?

Analysts wishing to participate should use the company-provided analysts' link to request Q&A access. According to the company, analysts must register through that link to be eligible to ask questions during the live call.

When will the replay of REGENXBIO's (RGNX) March 5, 2026 conference call be available?

A replay of the webcast will be available about two hours after the call ends. According to the company, the replay will be posted on the company's investor website for later listening and review.

Is there recommended timing for joining REGENXBIO's (RGNX) March 5 conference call?

Participants are advised to join the webcast 15 minutes prior to the scheduled 8:00 a.m. ET start time. According to the company, joining early helps ensure connection, registration verification, and timely access to the live presentation and Q&A.